Open access · CC-BY via OpenAlex

Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita

Payal P. Khincha, Alison A. Bertuch, Shahinaz M. Gadalla, Neelam Giri, Blanche P. Alter, Sharon A. Savage

Blood Advances · 2018 · ▲ 36 citations

Telomere attrition Human

Abstract

= .24). The results were similar for each individual leukocyte subset evaluated. In summary, our data show the expected age-associated longitudinal telomere shortening in patients with DC, irrespective of androgen therapy. Caution is warranted when recommending androgen therapy for non-BMF manifestations of DC or TBDs until the biological mechanisms are better understood.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: OpenAlex
DOI: 10.1182/bloodadvances.2018016964
Canonical: link ↗
Fetched: 2026-06-10 MST

Cite this

APA

Khincha, P.P., Bertuch, A.A., Gadalla, S.M., Giri, N., Alter, B.P., & Savage, S.A. (2018). Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. <em>Blood Advances</em>. https://doi.org/10.1182/bloodadvances.2018016964

Vancouver

Khincha PP, Bertuch AA, Gadalla SM, Giri N, Alter BP, Savage SA. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Advances. 2018. doi:10.1182/bloodadvances.2018016964.

BibTeX

@article{payal2018Simila, title = {Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita}, author = {Payal P. Khincha and Alison A. Bertuch and Shahinaz M. Gadalla and Neelam Giri and Blanche P. Alter and Sharon A. Savage}, journal = {Blood Advances}, year = {2018}, doi = {10.1182/bloodadvances.2018016964}, }